GeneDx Q4 EPS Surges 27% to $0.14 on $120.99M Revenue
GeneDx reported Q4 adjusted EPS of $0.14, beating the $0.11 consensus by 27% on $120.99M in revenue, 1.5% above estimates and up from $95.64M a year earlier. Shares have declined 36.9% YTD, underscoring investor focus on upcoming management commentary and future estimate revisions.
1. Q4 Financial Performance
GeneDx posted adjusted earnings of $0.14 per share for Q4, a 27% surprise over the $0.11 consensus estimate. Revenue reached $120.99 million, exceeding forecasts by 1.5% and marking a 26.5% increase from $95.64 million in the prior year period.
2. Consistent Estimate Surprises
This quarter marked the fourth consecutive beat of consensus EPS estimates, following a 75% earnings surprise in the prior quarter when the company delivered $0.49 per share versus a $0.28 forecast. Revenue has also topped estimates in each of the last four quarters, highlighting consistent execution.
3. Year-Over-Year Growth Dynamics
Revenue growth accelerated from $95.64 million in Q4 2024 to $120.99 million, driven by expanded service volumes in rare disease diagnostics. Adjusted EPS shifted from $0.07 a year earlier to $0.14, reflecting operational leverage despite a low-margin environment.
4. Stock Performance and Outlook
Shares are down 36.9% year-to-date as investors await management’s commentary on sustainability and future guidance. Consensus estimates call for a Q1 loss of $0.09 per share on $115.8 million in revenue and full-year 2026 EPS of $0.58 on $526.5 million, with the medical services industry ranked in the bottom 41% by growth prospects.